Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 85026
1. Gustafsson M, Sjölander M, Pfister B, Jonsson J, Schneede J, Lövheim H: Pharmacist participation in hospital ward teams and hospital readmission rates among people with dementia: a randomized controlled trial. Eur J Clin Pharmacol; 2017 Jul;73(7):827-835

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacist participation in hospital ward teams and hospital readmission rates among people with dementia: a randomized controlled trial.
  • PURPOSE: To assess whether comprehensive medication reviews conducted by clinical pharmacists as part of a healthcare team reduce drug-related hospital readmission rates among people with dementia or cognitive impairment.
  • Patients aged ≥65 years with dementia or cognitive impairment admitted to three wards at two hospitals located in Northern Sweden were included.
  • The primary outcome, risk of drug-related hospital readmissions, was assessed at 180 days of follow-up by intention-to-treat analysis.
  • CONCLUSION: Participation of clinical pharmacists in healthcare team conducting comprehensive medication reviews did not significantly reduce the risk of drug-related readmissions in patients with dementia or cognitive impairment; however, post-hoc and subgroup analyses indicated significant effects favoring the intervention.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharm World Sci. 2006 Jun;28(3):152-8 [17004023.001]
  • [Cites] Am J Geriatr Pharmacother. 2003 Dec;1(2):82-9 [15555470.001]
  • [Cites] J Eval Clin Pract. 2007 Oct;13(5):781-8 [17824872.001]
  • [Cites] Ann Pharmacother. 2002 Jul-Aug;36(7-8):1238-48 [12086559.001]
  • [Cites] Res Social Adm Pharm. 2014 Jul-Aug;10(4):608-22 [24161491.001]
  • [Cites] Clin Drug Investig. 2010;30(5):289-300 [20384385.001]
  • [Cites] Cochrane Database Syst Rev. 2013 Feb 28;(2):CD008986 [23450593.001]
  • [Cites] Arch Intern Med. 2009 May 11;169(9):894-900 [19433702.001]
  • [Cites] Arch Intern Med. 2008 Apr 14;168(7):687-94 [18413550.001]
  • [Cites] Med Care. 2010 Oct;48(10):923-33 [20720510.001]
  • [Cites] Cochrane Database Syst Rev. 2010 Jul 07;(7):CD000336 [20614422.001]
  • [Cites] Am J Geriatr Psychiatry. 2008 Jul;16(7):528-36 [18591573.001]
  • [Cites] Neurol Sci. 2009 Apr;30(2):87-92 [19229475.001]
  • [Cites] JAMA Intern Med. 2015 Nov;175(11):1803-12 [26368317.001]
  • [Cites] BMC Pharmacol Toxicol. 2013 Feb 08;14:10 [23391323.001]
  • [Cites] Arch Intern Med. 2005 Jan 10;165(1):68-74 [15642877.001]
  • [Cites] Eur J Clin Pharmacol. 2016 Sep;72 (9):1143-53 [27377393.001]
  • [Cites] JAMA. 2015 Oct 27;314(16):1681-2 [26505584.001]
  • [Cites] J Patient Saf. 2015 Mar 4;:null [25742062.001]
  • [Cites] Arch Intern Med. 1990 Apr;150(4):841-5 [2327844.001]
  • [Cites] Basic Clin Pharmacol Toxicol. 2013 Jun;112(6):359-73 [23506448.001]
  • [Cites] JAMA. 1998 Apr 15;279(15):1200-5 [9555760.001]
  • [Cites] PLoS One. 2014 Nov 07;9(11):e112282 [25379675.001]
  • [Cites] J Manag Care Pharm. 2013 Jun;19(5):408-16 [23697478.001]
  • [Cites] Lancet. 2007 Jul 14;370(9582):173-84 [17630041.001]
  • [Cites] Eur Heart J. 2006 Feb;27(4):434-40 [16230302.001]
  • [Cites] J Am Geriatr Soc. 2010 Apr;58(4):627-35 [20398146.001]
  • [Cites] Intern Med J. 2001 May-Jun;31(4):199-205 [11456032.001]
  • (PMID = 28391409.001).
  • [ISSN] 1432-1041
  • [Journal-full-title] European journal of clinical pharmacology
  • [ISO-abbreviation] Eur. J. Clin. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Clinical pharmacists / Dementia / Drug-related readmissions / Medication reviews / Old people
  •  go-up   go-down


2. Sommer I, Griebler U, Kien C, Auer S, Klerings I, Hammer R, Holzer P, Gartlehner G: Vitamin D deficiency as a risk factor for dementia: a systematic review and meta-analysis. BMC Geriatr; 2017 Jan 13;17(1):16
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin D deficiency as a risk factor for dementia: a systematic review and meta-analysis.
  • BACKGROUND: Sunlight exposure and high vitamin D status have been hypothesised to reduce the risk of developing dementia.
  • The objective of our research was to determine whether lack of sunlight and hypovitaminosis D over time are associated with dementia.
  • We conducted random effects meta-analyses of published and unpublished data to evaluate the influence of sunlight exposure or vitamin D as a surrogate marker on dementia risk.
  • RESULTS: We could not identify a single study investigating the association between sunlight exposure and dementia risk.
  • Six cohort studies provided data on the effect of serum vitamin D concentration on dementia risk.
  • The strength of evidence that serious vitamin D deficiency increases the risk of developing dementia, however, is very low due to the observational nature of included studies and their lack of adjustment for residual or important confounders (e.g.
  • ApoE ε4 genotype), as well as the indirect relationship between Vitamin D concentrations as a surrogate for sunlight exposure and dementia risk.
  • CONCLUSIONS: The results of this systematic review show that low vitamin D levels might contribute to the development of dementia.
  • Further research examining the direct and indirect relationship between sunlight exposure and dementia risk is needed.
  • Such research should involve large-scale cohort studies with homogeneous and repeated assessment of vitamin D concentrations or sunlight exposure and dementia outcomes.
  • [MeSH-major] Dementia / blood. Dementia / psychology. Sunlight. Vitamin D Deficiency / blood. Vitamin D Deficiency / psychology

  • MedlinePlus Health Information. consumer health - Dementia.
  • MedlinePlus Health Information. consumer health - Vitamin D Deficiency.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2007 Jul 19;357(3):266-81 [17634462.001]
  • [Cites] Nutr Bull. 2014 Dec;39(4):322-350 [25635171.001]
  • [Cites] J Clin Epidemiol. 2011 Dec;64(12):1277-82 [21802904.001]
  • [Cites] J Alzheimers Dis. 2013;33(3):659-74 [23042216.001]
  • [Cites] Ann N Y Acad Sci. 2016 Mar;1367(1):57-63 [27116242.001]
  • [Cites] Neurology. 2012 Sep 25;79(13):1397-405 [23008220.001]
  • [Cites] Syst Rev. 2015 Jan 01;4:1 [25554246.001]
  • [Cites] J Clin Epidemiol. 2011 Apr;64(4):407-15 [21247734.001]
  • [Cites] Front Mol Neurosci. 2015 Oct 07;8:58 [26468295.001]
  • [Cites] J Clin Epidemiol. 2010 May;63(5):474-5 [20189352.001]
  • [Cites] J Alzheimers Dis. 2014;42 Suppl 3:S53-61 [24898645.001]
  • [Cites] Eur J Neurol. 2014 Sep;21(9):1211-8, e69-70 [24846449.001]
  • [Cites] Epidemiology. 2014 Nov;25(6):799-804 [25215530.001]
  • [Cites] Neurology. 2014 Sep 2;83(10):920-8 [25098535.001]
  • [Cites] Eur J Clin Nutr. 2013 Mar;67(3):270-4 [23388663.001]
  • [Cites] PLoS One. 2013 Jun 21;8(6):e65785 [23805188.001]
  • [Cites] J Clin Epidemiol. 2011 Dec;64(12):1294-302 [21803546.001]
  • [Cites] J Clin Epidemiol. 2011 Dec;64(12):1311-6 [21802902.001]
  • [Cites] Lancet Neurol. 2016 Jan;15(1):116-24 [26300044.001]
  • [Cites] J Clin Epidemiol. 2011 Dec;64(12):1283-93 [21839614.001]
  • [Cites] J Chem Neuroanat. 2005 Jan;29(1):21-30 [15589699.001]
  • [Cites] J Cereb Blood Flow Metab. 2016 Jan;36(1):172-86 [26174330.001]
  • [Cites] Stroke. 2006 Feb;37(2):345-50 [16397184.001]
  • [Cites] Osteoporos Int. 2009 Nov;20(11):1807-20 [19543765.001]
  • [Cites] Clin Chem. 2012 Mar;58(3):531-42 [22230812.001]
  • [Cites] Alzheimers Dement. 2014 May;10(3):296-302 [23871764.001]
  • [Cites] Dement Geriatr Cogn Disord. 2011;32(4):273-8 [22261995.001]
  • [Cites] Am J Epidemiol. 2010 Apr 15;171(8):903-8 [20219763.001]
  • [Cites] J Bone Miner Res. 2012 Jun;27(6):1381-9 [22407786.001]
  • [Cites] Evid Rep Technol Assess (Full Rep). 2010 Apr;(193):1-727 [21500874.001]
  • [Cites] J Clin Epidemiol. 2011 Apr;64(4):401-6 [21208779.001]
  • [Cites] Am J Geriatr Pharmacother. 2010 Feb;8(1):4-33 [20226390.001]
  • [Cites] J Clin Epidemiol. 2011 Dec;64(12):1303-10 [21802903.001]
  • [Cites] Lancet Neurol. 2016 Apr;15(5):455-532 [26987701.001]
  • (PMID = 28086755.001).
  • [ISSN] 1471-2318
  • [Journal-full-title] BMC geriatrics
  • [ISO-abbreviation] BMC Geriatr
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  • [Keywords] NOTNLM ; Dementia / Meta-analysis / Systematic review / Vitamin D
  •  go-up   go-down


3. Kenawy S, Hegazy R, Hassan A, El-Shenawy S, Gomaa N, Zaki H, Attia A: Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin. PLoS One; 2017;12(8):e0183565
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin.
  • Age-related dementia is one of the most devastating disorders affecting the elderly.
  • Recently, emerging data suggest that impaired insulin signaling is the major contributor in the development of Alzheimer's dementia (AD), which is the most common type of senile dementia.
  • Reversing of these harmful effects by the use of insulin-sensitizing drugs like Met and Saxa suggests their involvement in alleviation insulin resistance as the underlying pathology of AD and hence their potential use as anti-dementia drugs.
  • [MeSH-major] Adamantane / analogs & derivatives. Aging / pathology. Dementia / chemically induced. Dipeptides / toxicity. Galactose / toxicity. Hypoglycemic Agents / therapeutic use. Insulin Resistance. Metformin / therapeutic use

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gerontologist. 2016 Apr;56 Suppl 2:S167-77 [26994258.001]
  • [Cites] Oxid Med Cell Longev. 2014;2014:320513 [24669284.001]
  • [Cites] Nat Med. 2004 Jul;10(7):719-26 [15195085.001]
  • [Cites] J Lab Clin Med. 1963 May;61:882-8 [13967893.001]
  • [Cites] J Alzheimers Dis. 2016;51(4):1197-208 [26967226.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2004 Mar;286(3):R431-44 [14761864.001]
  • [Cites] J Neurogenet. 2015;29(2-3):50-8 [26119401.001]
  • [Cites] Cold Spring Harb Perspect Med. 2016 Mar 01;6(3):a025932 [26931809.001]
  • [Cites] Neurobiol Learn Mem. 2011 Oct;96(3):432-42 [21907815.001]
  • [Cites] Mol Psychiatry. 2003 Sep;8(9):786-96 [12931206.001]
  • [Cites] Mol Neurobiol. 2017 Jan;54(1):255-271 [26738855.001]
  • [Cites] J Neurol Sci. 2006 Jun 15;245(1-2):21-33 [16631207.001]
  • [Cites] Mol Psychiatry. 2010 Nov;15(11):1046-52 [20966918.001]
  • [Cites] Vascul Pharmacol. 2016 Jan;76:62-71 [26455387.001]
  • [Cites] Neuropharmacology. 2016 Feb;101:123-36 [26211973.001]
  • [Cites] J Diabetes Complications. 2016 May-Jun;30(4):746-52 [26796432.001]
  • [Cites] J Ethnopharmacol. 2016 Feb 17;179:162-9 [26721223.001]
  • [Cites] Kidney Res Clin Pract. 2016 Jun;35(2):69-77 [27366660.001]
  • [Cites] Gerontologist. 1997 Apr;37(2):150-6 [9127971.001]
  • [Cites] CNS Neurol Disord Drug Targets. 2016;15(3):329-36 [26831258.001]
  • [Cites] Pharmacol Biochem Behav. 2012 Jun;101(4):564-74 [22425595.001]
  • [Cites] J Alzheimers Dis. 2005 Dec;8(3):247-68 [16340083.001]
  • [Cites] Curr Top Med Chem. 2016;16(5):485-92 [26268336.001]
  • [Cites] Behav Brain Res. 2011 Jun 20;220(1):30-41 [21262264.001]
  • [Cites] Expert Rev Neurother. 2010 May;10(5):683-91 [20420489.001]
  • [Cites] J Neurochem. 2004 Jun;89(6):1313-7 [15189333.001]
  • [Cites] Neuropharmacology. 2013 Sep;72:291-300 [23603201.001]
  • [Cites] Expert Opin Investig Drugs. 2015 Mar;24(3):393-9 [25586103.001]
  • [Cites] Curr Atheroscler Rep. 2016 Apr;18(4):16 [26888066.001]
  • [Cites] J Neuroimmunol. 1999 Jan 1;93(1-2):182-93 [10378882.001]
  • [Cites] Mol Neurobiol. 2016 Apr;53(3):1741-1752 [25744568.001]
  • [Cites] Anal Biochem. 1989 Aug 1;180(2):248-52 [2573290.001]
  • [Cites] Biotherapy. 1991;3(2):127-33 [2054253.001]
  • [Cites] Brain Res Bull. 2017 Jul;133:88-96 [27316747.001]
  • [Cites] Alzheimers Dement. 2016 Jun;12(6):719-32 [27179961.001]
  • [Cites] J Vis Exp. 2011 Jul 20;(53):null [21808223.001]
  • [Cites] Arch Neurol. 2011 Jan;68(1):51-7 [20837822.001]
  • [Cites] Anal Biochem. 1979 Jun;95(2):351-8 [36810.001]
  • [Cites] Cell Cycle. 2014;13(6):898-909 [24552807.001]
  • [Cites] J Pharm Sci. 1983 May;72(5):465-92 [6345750.001]
  • [Cites] J Nutr Health Aging. 2016 Apr;20(4):439-45 [26999245.001]
  • [Cites] Eur J Pharmacol. 2011 Jun 25;660(2-3):363-7 [21497160.001]
  • [Cites] Rev Neurosci. 2011;22(3):285-94 [21568789.001]
  • [Cites] J Cell Sci. 2001 Apr;114(Pt 8):1429-30 [11282018.001]
  • [Cites] Ann N Y Acad Sci. 2008 Apr;1126:147-51 [18448809.001]
  • [Cites] Lancet. 1994 Sep 17;344(8925):769-72 [7916070.001]
  • [Cites] J Alzheimers Dis. 2016;51(2):515-23 [26890783.001]
  • [Cites] PLoS One. 2015 Dec 02;10(12):e0143814 [26629991.001]
  • [Cites] Biomed Rep. 2016 May;4(5):519-522 [27123241.001]
  • [Cites] Mol Neurobiol. 2013 Dec;48(3):556-70 [23546742.001]
  • (PMID = 28832656.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Dipeptides; 0 / Hemoglobin A, Glycosylated; 0 / Hypoglycemic Agents; 0 / Nerve Tissue Proteins; 9100L32L2N / Metformin; 9GB927LAJW / saxagliptin; PJY633525U / Adamantane; X2RN3Q8DNE / Galactose
  •  go-up   go-down


Advertisement
4. Wang R, Chen Z, Fu Y, Wei X, Liao J, Liu X, He B, Xu Y, Zou J, Yang X, Weng R, Tan S, McElroy C, Jin K, Wang Q: Plasma Cystatin C and High-Density Lipoprotein Are Important Biomarkers of Alzheimer's Disease and Vascular Dementia: A Cross-Sectional Study. Front Aging Neurosci; 2017;9:26

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma Cystatin C and High-Density Lipoprotein Are Important Biomarkers of Alzheimer's Disease and Vascular Dementia: A Cross-Sectional Study.
  • <b>Objectives</b>: Cystatin C (Cys C) and high-density lipoprotein (HDL) play critical roles in neurodegenerative diseases, such as dementia, Alzheimer's disease (AD) and vascular dementia (VaD).
  • However, whether they can be used as reliable biomarkers to distinguish patients with dementia from healthy subjects and to determine disease severity remain largely unknown.
  • <b>Methods</b>: We conducted a cross-sectional study to determine plasma Cys C and HDL levels of 88 patients with dementia (43 AD patients, 45 VaD patients) and 45 healthy age-matched controls.
  • The severity of dementia was determined based on the Schwab and England Activities of Daily Living (ADL) Scale, the Mini-mental State Examination (MMSE), the Global Deterioration Scale (GDS), the Lawton Instrumental ADL (IADL) Scale, and the Hachinski Ischemia Scale (Hachinski).
  • Receiver operating characteristic (ROC) curves were calculated to determine the diagnostic accuracy of Cys C and HDL levels in distinguishing patients with dementia from healthy subjects.
  • <b>Conclusions</b>: Our findings suggest that the inflammatory mediators Cys C and HDL may play important roles in the pathogenesis of dementia, and plasma Cys C and HDL levels may be useful screening tools for differentiating AD/VaD patients from healthy subjects.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Front Aging Neurosci. 2015 Oct 27;7:203 [26578949.001]
  • [Cites] Curr Alzheimer Res. 2011 Mar;8(2):187-96 [21222606.001]
  • [Cites] J Alzheimers Dis. 2014;40(2):399-408 [24448787.001]
  • [Cites] Curr Alzheimer Res. 2014 May;11(4):340-8 [24720893.001]
  • [Cites] PLoS One. 2013;8(1):e55328 [23383156.001]
  • [Cites] Prog Neurobiol. 2013 Nov;110:2-28 [24036231.001]
  • [Cites] Neurology. 2008 Sep 30;71(14):1072-9 [18824671.001]
  • [Cites] Front Aging Neurosci. 2014 Jun 12;6:121 [24971061.001]
  • [Cites] Neurology. 1993 Feb;43(2):250-60 [8094895.001]
  • [Cites] Front Cell Neurosci. 2012 Dec 12;6:58 [23248582.001]
  • [Cites] Brain. 2011 Jan;134(Pt 1):258-77 [21186265.001]
  • [Cites] Front Cell Neurosci. 2014 Aug 14;8:231 [25177270.001]
  • [Cites] J Alzheimers Dis. 2010;21(2):471-8 [20555147.001]
  • [Cites] Cell Metab. 2014 Apr 1;19(4):574-91 [24508505.001]
  • [Cites] Neurology. 2014 Jul 1;83(1):40-7 [24907234.001]
  • [Cites] Front Mol Neurosci. 2012 Jul 06;5:79 [22783166.001]
  • [Cites] Front Aging Neurosci. 2016 Jul 28;8:179 [27516739.001]
  • [Cites] Neurobiol Aging. 2013 May;34(5):1389-96 [23273574.001]
  • [Cites] Front Aging Neurosci. 2010 Jul 15;2:null [20725527.001]
  • [Cites] J Alzheimers Dis. 2010;22(3):985-91 [20858959.001]
  • [Cites] J Neurochem. 2012 Aug;122(4):752-63 [22679891.001]
  • [Cites] Neurobiol Dis. 2014 Dec;72 Pt A:22-36 [25131449.001]
  • [Cites] Aging Dis. 2013 Mar 07;4(2):57-64 [23696950.001]
  • [Cites] Mol Neurodegener. 2015 Dec 01;10:64 [26627638.001]
  • [Cites] Mol Neurobiol. 2014 Apr;49(2):1043-54 [24203677.001]
  • [Cites] J Alzheimers Dis. 2009;16(2):389-97 [19221428.001]
  • [Cites] Front Cell Neurosci. 2015 Jul 06;9:247 [26217177.001]
  • [Cites] Front Biosci (Schol Ed). 2011 Jan 01;3:541-54 [21196395.001]
  • [Cites] Aging Dis. 2015 Oct 01;6(5):322-30 [26425387.001]
  • [Cites] PLoS One. 2013 Apr 23;8(4):e62354 [23626805.001]
  • [Cites] Neurology. 2014 Nov 11;83(20):1812-8 [25305153.001]
  • [Cites] Autophagy. 2011 Jul;7(7):788-9 [21464620.001]
  • [Cites] Sci Rep. 2016 Aug 04;6:30741 [27489174.001]
  • [Cites] Neurobiol Dis. 2005 Feb;18(1):152-65 [15649706.001]
  • [Cites] Am J Pathol. 2010 Nov;177(5):2256-67 [20889561.001]
  • [Cites] Front Aging Neurosci. 2013 Sep 09;5:50 [24058343.001]
  • [Cites] Nat Genet. 2007 Dec;39(12):1440-2 [18026100.001]
  • [Cites] Neurobiol Aging. 2011 Aug;32(8):1435-42 [19773092.001]
  • [Cites] Brain. 2014 Dec;137(Pt 12):3300-18 [25270989.001]
  • [Cites] Prog Neurobiol. 2015 Jul 21;:null [26209472.001]
  • [Cites] Neurology. 1984 Jul;34(7):939-44 [6610841.001]
  • (PMID = 28223934.001).
  • [ISSN] 1663-4365
  • [Journal-full-title] Frontiers in aging neuroscience
  • [ISO-abbreviation] Front Aging Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; Alzheimer’s disease / cystatin C / dementia / high-density lipoprotein / vascular dementia
  •  go-up   go-down


5. Karlsson S, Rahm Hallberg I, Midlöv P, Fagerström C: Trends in treatment with antipsychotic medication in relation to national directives, in people with dementia - a review of the Swedish context. BMC Psychiatry; 2017 Jul 14;17(1):251
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in treatment with antipsychotic medication in relation to national directives, in people with dementia - a review of the Swedish context.
  • BACKGROUND: The aim of this study was to explore trends in treatment with antipsychotic medication in Swedish dementia care in nursing homes as reported in the most recent empirical studies on the topic, and to relate these trends to directives from the national authorities.
  • The scoping review showed that treatment with antipsychotic drugs varied between 6% and 38%, and was higher in younger older persons and in those with moderate cognitive impairment and living in nursing homes for people with dementia.
  • CONCLUSIONS: Directives from the authorities in Sweden may have had an impact on treatment with antipsychotic medication for people with dementia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Health Serv Res. 2012 Oct;47(5):1791-813 [22946859.001]
  • [Cites] J Am Geriatr Soc. 2002 Jun;50(6):995-1000 [12110057.001]
  • [Cites] Int Psychogeriatr. 2009 Oct;21(5):941-8 [19586566.001]
  • [Cites] Arch Intern Med. 2007 Apr 9;167(7):676-83 [17420426.001]
  • [Cites] Int Psychogeriatr. 2010 Nov;22(7):1154-60 [20478102.001]
  • [Cites] Am J Geriatr Psychiatry. 2015 Dec;23(12):1259-69 [26525997.001]
  • [Cites] Lancet. 2005 Dec 17;366(9503):2112-7 [16360788.001]
  • [Cites] Int J Surg. 2010;8(5):336-41 [20171303.001]
  • [Cites] Dement Geriatr Cogn Disord. 2008;26(5):458-66 [18984956.001]
  • [Cites] Int J Geriatr Psychiatry. 2013 Jul;28(7):700-9 [22887592.001]
  • [Cites] BMC Public Health. 2012 Jan 23;12:68 [22269343.001]
  • [Cites] Ann Pharmacother. 2012 Jul-Aug;46(7-8):917-28 [22811347.001]
  • [Cites] Clin Drug Investig. 2010;30(5):289-300 [20384385.001]
  • [Cites] Health Serv Res. 2011 Dec;46(6pt1):1698-719 [21790590.001]
  • [Cites] Health Technol Assess. 2014 Jun;18(39):1-226, v-vi [24947468.001]
  • [Cites] Dement Geriatr Cogn Disord. 2004;17(1-2):78-90 [14566100.001]
  • [Cites] Aust N Z J Psychiatry. 2013 Jan;47(1):74-87 [23144164.001]
  • [Cites] Eur Neuropsychopharmacol. 2014 Jan;24(1):95-104 [24126116.001]
  • [Cites] Aging Clin Exp Res. 2004 Apr;16(2):158-68 [15195992.001]
  • [Cites] Int J Geriatr Psychiatry. 2009 Dec;24(12):1386-95 [19370714.001]
  • [Cites] BMC Pharmacol Toxicol. 2013 Nov 07;14:56 [24196341.001]
  • [Cites] Int J Geriatr Psychiatry. 2008 Mar;23(3):289-94 [17645282.001]
  • [Cites] Health Econ. 2012 Aug;21(8):977-93 [21882284.001]
  • [Cites] Int J Geriatr Psychiatry. 2001 Sep;16(9):900-6 [11571771.001]
  • [Cites] Int Psychogeriatr. 2011 Dec;23(10):1616-22 [21902862.001]
  • [Cites] Int Psychogeriatr. 2006 Dec;18(4):713-26 [16879762.001]
  • [Cites] JAMA. 1994 Feb 2;271(5):358-62 [8283585.001]
  • [Cites] Eur J Clin Pharmacol. 2016 Aug;72 (8):987-94 [27071994.001]
  • [Cites] Alzheimers Dement. 2012 Sep;8(5):453-7 [22285636.001]
  • [Cites] Health Serv Res. 2009 Apr;44(2 Pt 1):379-98 [19178586.001]
  • [Cites] BMC Pharmacol Toxicol. 2013 Feb 08;14:10 [23391323.001]
  • [Cites] Arch Gen Psychiatry. 2011 Feb;68(2):190-7 [21300946.001]
  • [Cites] Acta Psychiatr Scand. 2015 Jul;132(1):20-8 [25532774.001]
  • [Cites] Am J Alzheimers Dis Other Demen. 2011 Feb;26(1):10-28 [21282274.001]
  • [Cites] Dement Geriatr Cogn Disord. 2013;35(5-6):239-48 [23485654.001]
  • [Cites] J Am Med Dir Assoc. 2014;15(11):812-8 [25129474.001]
  • [Cites] PLoS Med. 2008 Apr 1;5(4):e76 [18384230.001]
  • [Cites] Int Psychogeriatr. 2013 Sep;25(9):1415-23 [23782794.001]
  • [Cites] Int J Geriatr Psychiatry. 2014 Mar;29(3):263-71 [23846797.001]
  • [Cites] JAMA. 2005 Feb 2;293(5):596-608 [15687315.001]
  • (PMID = 28705243.001).
  • [ISSN] 1471-244X
  • [Journal-full-title] BMC psychiatry
  • [ISO-abbreviation] BMC Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Antipsychotic medication / Dementia / Directive / Drug utilization
  •  go-up   go-down


6. Kryscio RJ, Abner EL, Caban-Holt A, Lovell M, Goodman P, Darke AK, Yee M, Crowley J, Schmitt FA: Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE). JAMA Neurol; 2017 May 01;74(5):567-573
Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE).
  • Importance: Oxidative stress is an established dementia pathway, but it is unknown if the use of antioxidant supplements can prevent dementia.
  • Objective: To determine if antioxidant supplements (vitamin E or selenium) used alone or in combination can prevent dementia in asymptomatic older men.
  • Design, Setting, and Participants: The Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADViSE) trial began as a double-blind randomized clinical trial in May 2002, which transformed into a cohort study from September 2009 to May 2015.
  • While taking study supplements, enrolled men visited their SELECT site and were evaluated for dementia using a 2-stage screen.
  • Main Outcomes and Measures: Dementia case ascertainment relied on a consensus review of the cognitive screens and medical records for men with suspected dementia who visited their physician for an evaluation or by review of all available information, including a functional assessment screen.
  • Dementia incidence (325 of 7338 men [4.4%]) was not different among the 4 study arms.
  • Conclusions and Relevance: Neither supplement prevented dementia.
  • To our knowledge, this is the first study to investigate the long-term association of antioxidant supplement use and dementia incidence among asymptomatic men.
  • [MeSH-major] Antioxidants / pharmacology. Dementia / prevention & control. Outcome Assessment (Health Care). Selenium / pharmacology. Vitamin E / pharmacology
  • [MeSH-minor] Aged. Alzheimer Disease / prevention & control. Dietary Supplements. Double-Blind Method. Drug Therapy, Combination. Humans. Longitudinal Studies. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Dementia.
  • MedlinePlus Health Information. consumer health - Vitamin E.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 2007 May 22;68(21):1800-8 [17460158.001]
  • [Cites] Toxicol Lett. 2014 Oct 15;230(2):295-303 [24269718.001]
  • [Cites] JAMA. 2008 Nov 19;300(19):2253-62 [19017911.001]
  • [Cites] Int J Geriatr Psychiatry. 2003 Apr;18(4):318-24 [12673608.001]
  • [Cites] J Intern Med. 2014 Mar;275(3):251-83 [24605808.001]
  • [Cites] Neurology. 1989 Sep;39(9):1159-65 [2771064.001]
  • [Cites] N Engl J Med. 1997 Apr 24;336(17):1216-22 [9110909.001]
  • [Cites] Free Radic Biol Med. 2009 Jun 1;46(11):1527-33 [19303433.001]
  • [Cites] Stat Med. 2004 Jan 30;23(2):285-96 [14716729.001]
  • [Cites] J Alzheimers Dis. 2011;26(1):81-104 [21593562.001]
  • [Cites] Alzheimers Dement. 2013 Nov;9(6):657-65 [23332672.001]
  • [Cites] J Intern Med. 2014 Mar;275(3):229-50 [24605807.001]
  • [Cites] Clin Trials. 2013 Feb;10(1):131-42 [23064404.001]
  • [Cites] Lancet Neurol. 2014 Aug;13(8):788-94 [25030513.001]
  • [Cites] J Nutr Biochem. 2007 Jul;18(7):482-7 [17142028.001]
  • [Cites] J Geriatr Psychiatry Neurol. 1999 Winter;12(4):168-79 [10616864.001]
  • [Cites] Lancet. 2015 Jun 6;385(9984):2255-63 [25771249.001]
  • [Cites] Alzheimers Dement. 2007 Jul;3(3):186-91 [19595937.001]
  • [Cites] Mol Aspects Med. 2004 Feb-Apr;25(1-2):117-23 [15051321.001]
  • [Cites] Arch Neurol. 2012 Jul;69(7):836-41 [22431837.001]
  • [Cites] Lancet Neurol. 2012 Oct;11(10 ):851-9 [22959217.001]
  • [Cites] Neurology. 2005 Aug 23;65(4):559-64 [16116116.001]
  • [Cites] J Steroid Biochem Mol Biol. 2010 Feb 28;118(4-5):304-10 [19932751.001]
  • [Cites] Neurobiol Aging. 2003 Nov;24(7):915-9 [12928050.001]
  • [Cites] Arch Neurol. 2007 May;64(5):725-30 [17502472.001]
  • [Cites] Ann Intern Med. 2005 Jan 4;142(1):37-46 [15537682.001]
  • [Cites] JAMA Neurol. 2014 Aug;71(8):947-9 [24886838.001]
  • [Cites] Curr Aging Sci. 2011 Jul;4(2):158-70 [21235492.001]
  • [Cites] Int Psychogeriatr. 2013 Jul;25(7):1115-23 [23570673.001]
  • [Cites] Am J Epidemiol. 2007 Apr 15;165(8):955-65 [17272290.001]
  • [Cites] Neurology. 1999 Jan 15;52(2):231-8 [9932936.001]
  • [Cites] N Engl J Med. 2005 Jun 9;352(23):2379-88 [15829527.001]
  • [Cites] J Geriatr Psychiatry Neurol. 1998 Spring;11(1):18-24 [9686748.001]
  • [Cites] Arch Neurol. 2010 Nov;67(11):1364-9 [21060013.001]
  • [Cites] Alzheimer Dis Assoc Disord. 2009 Jan-Mar;23(1):38-43 [18695589.001]
  • [Cites] Am J Clin Nutr. 1983 May;37(5):872-81 [6846228.001]
  • [Cites] JAMA. 2009 Jan 7;301(1):39-51 [19066370.001]
  • [Cites] Alzheimers Dement (Amst). 2015 Jun;1(2):236-241 [26258162.001]
  • [Cites] J Nutr Health Aging. 2013 Jan;17(1):72-5 [23299383.001]
  • (PMID = 28319243.001).
  • [ISSN] 2168-6157
  • [Journal-full-title] JAMA neurology
  • [ISO-abbreviation] JAMA Neurol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA037429; United States / NCI NIH HHS / CA / UG1 CA189974; United States / NIA NIH HHS / AG / R01 AG038651; United States / NIA NIH HHS / AG / P30 AG028383; United States / NCI NIH HHS / CA / UM1 CA182883
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 1406-18-4 / Vitamin E; H6241UJ22B / Selenium
  •  go-up   go-down


7. Yang JS, Wu XH, Yu HG, Teng LS: Tangeretin inhibits neurodegeneration and attenuates inflammatory responses and behavioural deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease dementia in rats. Inflammopharmacology; 2017 Aug;25(4):471-484
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tangeretin inhibits neurodegeneration and attenuates inflammatory responses and behavioural deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease dementia in rats.
  • Our aim was to investigate whether tangeretin, a citrus flavonoid, was able to prevent neuroinflammation and improve dementia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced rodent model of Parkinson's disease (PD).
  • The experimental data suggest tangeretin as an effective candidate drug with potential for prevention and treatment of neuroinflammation and dementia associated with PD.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Behav Brain Res. 2011 Jun 1;219(2):280-90 [21262271.001]
  • [Cites] Neurotox Res. 2016 Feb;29(2):275-87 [26607911.001]
  • [Cites] Neurosci Lett. 2000 Jun 23;287(2):117-20 [10854726.001]
  • [Cites] Behav Brain Res. 2008 Apr 9;188(2):310-5 [18178264.001]
  • [Cites] J Neurosci Methods. 2005 Oct 15;148(1):78-87 [15939479.001]
  • [Cites] Behav Brain Res. 1988 Nov 1;31(1):47-59 [3228475.001]
  • [Cites] Eur J Neurosci. 2001 Feb;13(3):529-38 [11168560.001]
  • [Cites] J Agric Food Chem. 2008 Aug 13;56(15):6185-205 [18593176.001]
  • [Cites] Clin Neurosci Res. 2006 Dec 6;6(5):261-281 [18060039.001]
  • [Cites] Neuroscience. 2004;127(2):289-300 [15262320.001]
  • [Cites] J Neurol. 2000 Apr;247 Suppl 2:II25-35 [10991662.001]
  • [Cites] Glia. 2005 Nov 1;52(2):144-52 [15920722.001]
  • [Cites] Trends Mol Med. 2013 Mar;19(3):187-96 [23318001.001]
  • [Cites] Acta Anaesthesiol Scand. 2013 Mar;57(3):380-90 [23186353.001]
  • [Cites] Front Biosci. 2003 Sep 01;8:s992-7 [12957858.001]
  • [Cites] Behav Brain Res. 2014 Jul 15;268:177-84 [24755306.001]
  • [Cites] Eur J Neurosci. 2003 Sep;18(5):1175-88 [12956716.001]
  • [Cites] Neurobiol Aging. 2012 Aug;33(8):1777-91 [21524431.001]
  • [Cites] Neurosci Lett. 1998 Jun 26;250(1):25-8 [9696057.001]
  • [Cites] Neuropsychologia. 2003;41(5):565-74 [12559149.001]
  • [Cites] J Neurosci. 2005 Mar 2;25(9):2322-9 [15745958.001]
  • [Cites] Behav Brain Res. 2001 Sep 28;124(1):9-18 [11423161.001]
  • [Cites] FASEB J. 2003 Mar;17 (3):500-2 [12631585.001]
  • [Cites] Eur J Pharmacol. 2003 Dec 15;482(1-3):215-22 [14660025.001]
  • [Cites] Neuroscience. 1999 Jan;88(1):1-16 [10051185.001]
  • [Cites] Exp Neurol. 2005 Oct;195(2):322-9 [16005872.001]
  • [Cites] Lancet Neurol. 2003 Apr;2(4):229-37 [12849211.001]
  • [Cites] Parkinsonism Relat Disord. 2004 May;10 Suppl 1:S3-7 [15109580.001]
  • [Cites] Mediators Inflamm. 2013;2013:952375 [23935251.001]
  • [Cites] FASEB J. 2006 Apr;20(6):670-82 [16581975.001]
  • [Cites] Restor Neurol Neurosci. 2013;31(1):87-97 [23047495.001]
  • [Cites] J Neuroimmunol. 2008 Nov 15;204(1-2):43-51 [18817984.001]
  • [Cites] Food Chem Toxicol. 2014 Sep;71:176-82 [24955543.001]
  • [Cites] Cancer Chemother Pharmacol. 2015 Feb;75(2):263-72 [25431347.001]
  • [Cites] Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S210-2 [22166438.001]
  • [Cites] J Food Sci. 2016 May;81(5):H1320-7 [27095513.001]
  • [Cites] Neuroimage. 2006 Oct 15;33(1):374-82 [16904344.001]
  • [Cites] Behav Neurosci. 1988 Oct;102(5):748-59 [2904271.001]
  • [Cites] Acta Neuropathol. 2003 Dec;106(6):518-26 [14513261.001]
  • [Cites] Behav Brain Res. 2012 Apr 1;229(1):41-7 [22227506.001]
  • [Cites] Neurobiol Learn Mem. 2008 Feb;89(2):192-8 [17702614.001]
  • [Cites] Brain Res Bull. 2001 May 1;55(1):101-6 [11427344.001]
  • [Cites] J Neurosci. 2004 May 12;24(19):4596-604 [15140931.001]
  • [Cites] Hippocampus. 2005;15(8):1050-6 [16145694.001]
  • [Cites] J Neurosci Res. 1999 May 15;56(4):441-6 [10340751.001]
  • [Cites] Behav Brain Res. 2006 Apr 25;169(1):142-9 [16455144.001]
  • [Cites] Curr Alzheimer Res. 2005 Jul;2(3):355-65 [15974901.001]
  • [Cites] Neurobiol Learn Mem. 2008 May;89(4):522-32 [18304843.001]
  • [Cites] Neuroscience. 2005;133(3):831-40 [15893432.001]
  • [Cites] Prog Neurobiol. 2000 Sep;62(1):63-88 [10821982.001]
  • [Cites] Immunopharmacology. 1998 Jun;39(3):167-80 [9754903.001]
  • [Cites] Neuropharmacology. 2008 Mar;54(3):620-7 [18164319.001]
  • [Cites] Neuroreport. 2001 Dec 4;12(17):3871-5 [11726811.001]
  • [Cites] J Neurosci. 2000 Aug 1;20(15):5715-23 [10908611.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1988 Dec;51(12):1498-502 [3221216.001]
  • [Cites] Behav Brain Res. 2010 Mar 17;208(1):38-46 [19900486.001]
  • [Cites] Neurosci Res. 2006 Sep;56(1):96-102 [16846658.001]
  • [Cites] Neurology. 2005 Apr 26;64(8):1404-10 [15851731.001]
  • [Cites] Exp Neurol. 2005 Mar;192(1):134-41 [15698627.001]
  • [Cites] Brain Res. 2000 Mar 31;860(1-2):190-4 [10727642.001]
  • [Cites] Biomed Pharmacother. 2016 Jul;81:491-6 [27261630.001]
  • [Cites] Neuropharmacology. 2015 Apr;91:43-56 [25499022.001]
  • [Cites] Nat Neurosci. 2001 Jul;4(7):702-10 [11426226.001]
  • [Cites] J Neural Transm Suppl. 2000;(58):143-51 [11128604.001]
  • [Cites] Am J Psychiatry. 1995 Sep;152(9):1291-7 [7653683.001]
  • [Cites] Ann Neurol. 1999 Oct;46(4):598-605 [10514096.001]
  • [Cites] Dev Neurosci. 1998;20(1):1-18 [9600386.001]
  • [Cites] Neurobiol Dis. 2008 Nov;32(2):319-27 [18718537.001]
  • [Cites] Nat Rev Neurol. 2010 Apr;6(4):193-201 [20234358.001]
  • [Cites] J Am Assoc Lab Anim Sci. 2011 Jan;50(1):41-5 [21333162.001]
  • [Cites] Behav Neurosci. 2009 Dec;123(6):1261-70 [20001109.001]
  • [Cites] Pharmacol Biochem Behav. 2010 Apr;95(2):158-65 [20064549.001]
  • [Cites] Eur J Pharmacol. 2008 Oct 10;594(1-3):101-8 [18674531.001]
  • [Cites] Phytother Res. 2013 Apr;27(4):564-71 [22678994.001]
  • [Cites] Parkinsonism Relat Disord. 2005 Jun;11 Suppl 1:S9-S15 [15885630.001]
  • [Cites] Br J Pharmacol. 2007 Apr;150(8):963-76 [17339843.001]
  • [Cites] Acta Neuropathol. 2005 Feb;109(2):141-50 [15619128.001]
  • [Cites] Mol Genet Metab. 1998 Feb;63(2):142-7 [9562968.001]
  • [Cites] Glia. 2004 May;46(4):402-9 [15095370.001]
  • [Cites] Neurotoxicology. 2012 Mar;33(2):147-55 [22281204.001]
  • [Cites] Neurosci Lett. 2003 May 1;341(2):87-90 [12686372.001]
  • [Cites] Mov Disord. 2006 Sep;21(9):1483-7 [16705661.001]
  • [Cites] Pharmacol Biochem Behav. 2012 Jul;102(1):64-71 [22487770.001]
  • [Cites] J Neuroimmune Pharmacol. 2016 Jun;11(2):294-305 [26899309.001]
  • (PMID = 28577132.001).
  • [ISSN] 1568-5608
  • [Journal-full-title] Inflammopharmacology
  • [ISO-abbreviation] Inflammopharmacology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) / Dementia / Inflammatory cytokines / Neurodegeneration / Parkinson’s disease / Tangeretin
  •  go-up   go-down


8. Allers K, Dörks M, Schmiemann G, Hoffmann F: Antipsychotic drug use in nursing home residents with and without dementia: keep an eye on the pro re nata medication. Int Clin Psychopharmacol; 2017 Jul;32(4):213-218

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antipsychotic drug use in nursing home residents with and without dementia: keep an eye on the pro re nata medication.
  • Behavioral and psychological symptoms of dementia often lead to the prescription of antipsychotics, especially in nursing homes, but their use remains controversial.
  • This study aimed to assess antipsychotic drug use in residents with dementia compared with those without dementia.
  • Overall, 57.5% of the 837 residents had a diagnosis of dementia and 47.0% of residents with dementia and 19.5% of those without dementia received antipsychotics.
  • 35.9% of all antipsychotics in residents with dementia were prescribed as pro re nata (PRN) compared with 23.0% for residents without dementia.
  • The adjusted logistic regression showed a significant association between the prescription of antipsychotics and dementia (odds ratio: 3.58, 95% confidence interval: 2.45-5.25) as well as severe care dependency (odds ratio: 1.68, 95% confidence interval: 1.10-2.55).
  • Despite safety warnings, antipsychotics are still frequently prescribed to residents with dementia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28346296.001).
  • [ISSN] 1473-5857
  • [Journal-full-title] International clinical psychopharmacology
  • [ISO-abbreviation] Int Clin Psychopharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Ammann EM, Pottala JV, Robinson JG, Espeland MA, Harris WS: Erythrocyte omega-3 fatty acids are inversely associated with incident dementia: Secondary analyses of longitudinal data from the Women's Health Initiative Memory Study (WHIMS). Prostaglandins Leukot Essent Fatty Acids; 2017 Jun;121:68-75
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erythrocyte omega-3 fatty acids are inversely associated with incident dementia: Secondary analyses of longitudinal data from the Women's Health Initiative Memory Study (WHIMS).
  • OBJECTIVE: To assess whether red blood cell (RBC) docosahexaenoic acid and eicosapentaenoic acid (DHA+EPA) levels have a protective association with the risk of dementia in older women.
  • Cox regression was used to quantify the association between RBC DHA+EPA and the risk of probable dementia, independent of major dementia risk factors.
  • RESULTS: During a median follow-up period of 9.8 years, 587 incident cases of probable dementia were identified.
  • After adjusting for demographic, clinical, and behavioral risk factors, a one standard deviation increase in DHA+EPA levels was associated with a significantly lower risk of dementia (HR = 0.92, 95% CI: 0.84, 1.00; p < 0.05).
  • For women with high DHA+EPA exposure (1SD above mean) compared to low exposure (1SD below mean), the adjusted 15-year absolute risk difference for dementia was 2.1% (95% CI: 0.2%, 4.0%).
  • DISCUSSION: Higher levels of DHA+EPA may help protect against the development of dementia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • [Cites] Epidemiology. 2010 Jan;21(1):13-5 [20010207.001]
  • [Cites] Biochim Biophys Acta. 2015 Jan;1848(1 Pt B):211-9 [24820775.001]
  • [Cites] JAMA. 2016 Feb 2;315(5):489-97 [26836731.001]
  • [Cites] J Alzheimers Dis. 2003 Aug;5(4):315-22 [14624027.001]
  • [Cites] Alzheimers Res Ther. 2016 Jun 30;8:25 [27358067.001]
  • [Cites] J Nutr Health Aging. 2011 Jan;15(1):25-31 [21267518.001]
  • [Cites] J Alzheimers Dis. 2012;29(3):691-7 [22466064.001]
  • [Cites] Lipids. 2012 Sep;47(9):835-46 [22782370.001]
  • [Cites] Biostatistics. 2006 Jan;7(1):29-40 [15923407.001]
  • [Cites] Atherosclerosis. 2013 May;228(1):181-7 [23466070.001]
  • [Cites] JAMA. 2004 Jun 23;291(24):2947-58 [15213206.001]
  • [Cites] FEBS Lett. 2016 Feb;590(4):582-91 [26821608.001]
  • [Cites] Biochim Biophys Acta. 2015 Apr;1851(4):397-413 [25139562.001]
  • [Cites] Prev Med. 2004 Jul;39(1):212-20 [15208005.001]
  • [Cites] Nat Neurosci. 2012 Jan 29;15(3):349-57 [22286176.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2010 Feb 25;56(1):59-82 [20196971.001]
  • [Cites] Am J Clin Nutr. 2008 Jul;88(1):216-23 [18614744.001]
  • [Cites] Am J Clin Nutr. 2016 Feb;103(2):330-40 [26718417.001]
  • [Cites] J Clin Psychiatry. 2012 Sep;73(9):1245-54 [22938939.001]
  • [Cites] Am J Clin Nutr. 2008 Feb;87(2):449-54 [18258638.001]
  • [Cites] Biomed Res Int. 2015;2015:172801 [26301243.001]
  • [Cites] Am J Clin Nutr. 2003 Apr;77(4):803-8 [12663275.001]
  • [Cites] Neurosci Biobehav Rev. 2015 Jan;48:1-9 [25446949.001]
  • [Cites] JAMA. 2004 Apr 14;291(14):1701-12 [15082697.001]
  • [Cites] JAMA. 2002 Jul 17;288(3):321-33 [12117397.001]
  • [Cites] FEBS J. 2011 Oct;278(20):3905-17 [21722314.001]
  • [Cites] Diabetes Care. 2015 Dec;38(12 ):2316-24 [26486190.001]
  • [Cites] Aust Prescr. 2015 Apr;38(2):60-3 [26648618.001]
  • [Cites] J Clin Psychiatry. 1987 Aug;48(8):314-8 [3611032.001]
  • [Cites] Ann Epidemiol. 1999 Apr;9(3):178-87 [10192650.001]
  • [Cites] Am J Clin Nutr. 2007 Apr;85(4):1103-11 [17413112.001]
  • [Cites] Arch Neurol. 1998 Mar;55(3):360-5 [9520010.001]
  • [Cites] Eur J Clin Nutr. 2014 Apr;68(4):503-9 [24398640.001]
  • [Cites] Neurology. 2014 Feb 4;82(5):435-42 [24453077.001]
  • [Cites] Am J Clin Nutr. 2006 Jun;83(6 Suppl):1467S-1476S [16841856.001]
  • [Cites] Lipids. 2000 Dec;35(12):1305-12 [11201991.001]
  • [Cites] Neurology. 2012 Feb 28;78(9):658-64 [22371413.001]
  • [Cites] Neurology. 2013 Oct 22;81(17):1484-91 [24068783.001]
  • [Cites] JAMA. 2004 Jun 23;291(24):2959-68 [15213207.001]
  • [Cites] Biochem Pharmacol. 2014 Apr 15;88(4):640-51 [24398425.001]
  • [Cites] Neurology. 1997 Dec;49(6):1498-504 [9409336.001]
  • [Cites] FASEB J. 2015 Jul;29(7):2681-9 [25805829.001]
  • [Cites] Neurobiol Aging. 2012 Jul;33(7):1482.e17-29 [22305186.001]
  • [Cites] Arch Neurol. 2006 Nov;63(11):1545-50 [17101822.001]
  • [Cites] Nutr Res. 2016 Sep;36(9):989-994 [27632919.001]
  • [Cites] Am J Clin Nutr. 2008 Sep;88(3):714-21 [18779288.001]
  • (PMID = 28651700.001).
  • [ISSN] 1532-2823
  • [Journal-full-title] Prostaglandins, leukotrienes, and essential fatty acids
  • [ISO-abbreviation] Prostaglandins Leukot. Essent. Fatty Acids
  • [Language] eng
  • [Grant] United States / WHI NIH HHS / WH / HHSN268200900036C
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Keywords] NOTNLM ; All cognitive disorders/dementia / Alzheimer's Disease / Biomarkers / Cohort studies / Omega-3 fatty acids / Women
  •  go-up   go-down


10. Hewer W, Thomas C: [Treatment with psychotropic agents in patients with dementia and delirium : Gap between guideline recommendations and treatment practice]. Z Gerontol Geriatr; 2017 Feb;50(2):106-114

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment with psychotropic agents in patients with dementia and delirium : Gap between guideline recommendations and treatment practice].
  • [Transliterated title] Psychopharmakotherapie bei Demenz und Delir : Im Spannungsfeld zwischen Leitlinienempfehlungen und Versorgungspraxis.
  • BACKGROUND AND OBJECTIVES: Psychiatric symptoms in dementia and delirium are associated with a substantially reduced quality of life of patients and their families and often challenging for professionals.
  • MATERIAL AND METHODS: Narrative review with special reference to the German dementia guideline from 2016 and recently published practice guidelines for delirium in old age in German and English language.
  • RESULTS: The indications for use of psychotropic agents, especially antipsychotics, are defined narrowly in the German dementia guideline.
  • Comparable to the German dementia guideline they recommend general medical interventions and nonpharmacological treatment as first line measures and the use of psychotropic agents only under certain conditions.
  • CONCLUSION: The guidelines discussed here advocate well-founded a cautious prescription of psychotropic agents in patients with dementia and delirium.
  • Most notably, however, epidemiological data disclose an unacceptable rate of hazardous overtreatment with psychotropic agents, especially in long-term care of persons with dementia.
  • [MeSH-major] Delirium / drug therapy. Dementia / drug therapy. Drug Monitoring / standards. Geriatrics / standards. Practice Guidelines as Topic. Psychotropic Drugs / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Psychiatry. 2016 May 1;173(5):543-6 [27133416.001]
  • [Cites] Int J Geriatr Psychiatry. 2014 Mar;29(3):253-62 [23801358.001]
  • [Cites] Z Gerontol Geriatr. 2016 Jan;49(1):52-8 [25801513.001]
  • [Cites] Int Psychogeriatr. 2013 Dec;25(12):2067-75 [23962713.001]
  • [Cites] Crit Care Med. 2013 Jan;41(1):263-306 [23269131.001]
  • [Cites] Lancet. 2014 Mar 8;383(9920):911-22 [23992774.001]
  • [Cites] Int J Clin Pharmacol Ther. 2016 Nov;54(11):835-840 [27487368.001]
  • [Cites] JAMA. 2005 Oct 19;294(15):1934-43 [16234500.001]
  • [Cites] J Am Coll Surg. 2015 Feb;220(2):136-48.e1 [25535170.001]
  • [Cites] J Am Med Dir Assoc. 2015 Aug 1;16(8):697-701 [25933727.001]
  • [Cites] Palliat Support Care. 2011 Dec;9(4):351-7 [22104410.001]
  • [Cites] Z Gerontol Geriatr. 2015 Jun;48(4):305-11 [25962363.001]
  • [Cites] Int Psychogeriatr. 2013 Apr;25(4):635-43 [23253513.001]
  • [Cites] Br J Psychiatry. 2014 Dec;205(6):478-85 [25359923.001]
  • [Cites] Lancet Psychiatry. 2014 Sep 1;1(4):312-315 [25285270.001]
  • [Cites] N Engl J Med. 2012 Oct 18;367(16):1497-507 [23075176.001]
  • [Cites] JAMA Psychiatry. 2015 May;72 (5):438-45 [25786075.001]
  • [Cites] Drugs Real World Outcomes. 2016 May 13;3(2):175-182 [27398296.001]
  • [Cites] Br J Psychiatry. 2009 Mar;194(3):212-9 [19252147.001]
  • [Cites] Eur Neuropsychopharmacol. 2015 Dec;25(12 ):2333-8 [26476703.001]
  • [Cites] Int Psychogeriatr. 2015 Nov;27(11):1849-59 [26062126.001]
  • [Cites] Nervenarzt. 2010 May;81(5):613-28; quiz 629-30 [20454878.001]
  • [Cites] Pharmacopsychiatry. 2012 Jul;45(5):182-8 [22430201.001]
  • [Cites] J Psychosom Res. 2014 Sep;77(3):240-1 [25149034.001]
  • [Cites] J Am Geriatr Soc. 2016 Apr;64(4):705-14 [27004732.001]
  • [Cites] Z Gerontol Geriatr. 2015 Jun;48(4):312-7 [25957245.001]
  • [Cites] Nervenarzt. 2016 May;87(5):534-42 [26628044.001]
  • [Cites] Pharmacotherapy. 2015 Aug;35(8):731-9 [26238778.001]
  • (PMID = 28124100.001).
  • [ISSN] 1435-1269
  • [Journal-full-title] Zeitschrift fur Gerontologie und Geriatrie
  • [ISO-abbreviation] Z Gerontol Geriatr
  • [Language] ger
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Psychotropic Drugs
  • [Keywords] NOTNLM ; Administration and dosage / Drug monitoring / Evidence-based medicine / Nonpharmacological treatment
  •  go-up   go-down






Advertisement